SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0001140361-23-007028
Filing Date
2023-02-14
Accepted
2023-02-14 17:08:42
Documents
2
Group Members
BAM PARTNERS TRUSTBROOKFIELD ASSET MANAGEMENT INC.OAKTREE CAPITAL GROUP HOLDINGS GP, LLCOAKTREE CAPITAL I, L.P.OAKTREE FUND GP I, L.P.OAKTREE FUND GP, LLCOAKTREE HOLDINGS, LLCOCM HOLDINGS I, LLCOCM VALUE SPAC HOLDINGS, L.P.

Document Format Files

Seq Description Document Type Size
1 SC 13G/A brhc10048172_sc13ga.htm SC 13G/A 348451
2 EXHIBIT 1 brhc10048172_ex1.htm EX-99.1 24751
  Complete submission text file 0001140361-23-007028.txt   375247
Mailing Address 333 SOUTH GRAND AVENUE 28TH FLOOR LOS ANGELES CA 90071
Business Address 333 SOUTH GRAND AVENUE 28TH FLOOR LOS ANGELES CA 90071 (213) 830-6300
Oaktree Capital Group, LLC (Filed by) CIK: 0001403528 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13G/A
SIC: 6282 Investment Advice

Mailing Address 217 W. MAIN STREET SOMERVILLE NJ 08876
Business Address 217 W. MAIN STREET SOMERVILLE NJ 08876 908-370-5102
ZyVersa Therapeutics, Inc. (Subject) CIK: 0001859007 (see all company filings)

IRS No.: 862685744 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13G/A | Act: 34 | File No.: 005-93211 | Film No.: 23631394
SIC: 2834 Pharmaceutical Preparations